Omeros has filed a patent for novel chimeric molecules of ficolin-associated polypeptides. These fusion polypeptides can be used in the treatment of various conditions such as inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The patent also covers the nucleic acid molecules encoding these fusion polypeptides, as well as the vectors and host cells used in their production. The claim specifically focuses on a method of treating autoimmune disorders by administering a composition containing a chimeric molecule of a ficolin-associated polypeptide, which includes an inhibitor of complement activation. This chimeric molecule is designed to inhibit complement activation in subjects with autoimmune disorders. GlobalData’s report on Omeros gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Omeros, Peptide pharmacophores was a key innovation area identified from patents. Omeros's grant share as of September 2023 was 44%. Grant share is based on the ratio of number of grants to total number of patents.
A patent filed for a method of treating autoimmune disorders
A recently filed patent (Publication Number: US20230295252A1) describes a method for treating autoimmune disorders using a specific composition. The method involves administering a composition that contains a chimeric molecule of a ficolin-associated polypeptide and an inhibitor of complement activation. This chimeric molecule inhibits complement activation in individuals suffering from autoimmune disorders.
The chimeric molecule of the ficolin-associated polypeptide consists of a human ficolin-associated polypeptide with a specific amino acid sequence or a variant thereof that has at least 80% sequence identity to the specified amino acid sequence. Additionally, the composition includes an inhibitor of complement activation, which can be selected from a list of options such as Factor H, GAS6, Protein S, C1-inhibitor, complement component 4 binding protein, Factor I, CR1, DAF(CD55), CD59, CR2, or a fragment thereof that inhibits complement activation.
The ficolin-associated polypeptide in the composition can have different amino acid sequences, such as residues 20-297 of a specific sequence or residues 20-380 of another specific sequence, or functional variants thereof with at least 80% sequence identity. It can also be in the form of a homodimer or consist of the amino acid sequence of residues 20-380 of a specific sequence. Alternatively, the ficolin-associated polypeptide can have the amino acid sequence of a specific sequence or variants or immunologic fragments thereof with at least 80% sequence identity to that specific sequence.
The ficolin-associated polypeptide and the inhibitor of complement activation can be directly fused to each other as a fusion protein. In specific embodiments, the inhibitor of complement activation can be Factor H or a fragment thereof that inhibits complement activation, where the fragment of Factor H includes at least the first four SCR domains of Factor H.
The method described in the patent can be used to treat various autoimmune disorders, including Addison's disease, autoimmune hemolytic anemia, autoimmune thyroiditis, Crohn's disease, Graves' disease, Guillain-Barre syndrome, systemic lupus erythematosus, lupus nephritis, multiple sclerosis, myasthenia gravis, psoriasis, primary biliary cirrhosis, rheumatoid arthritis, uveitis, asthma, atherosclerosis, type I diabetes, psoriasis, and allergies.
In summary, the patent describes a method for treating autoimmune disorders by administering a composition containing a specific chimeric molecule of a ficolin-associated polypeptide and an inhibitor of complement activation. The method offers potential therapeutic options for individuals suffering from a range of autoimmune disorders.
To know more about GlobalData’s detailed insights on Omeros, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
